0 160

Cited 0 times in

MARIPOSA-2: Randomized phase III study of amivantamab plus lazertinib plus chemotherapy vs chemotherapy alone in EGFRmutant NSCLC after osimertinib failure

DC Field Value Language
dc.date.accessioned2023-06-02T01:01:42Z-
dc.date.available2023-06-02T01:01:42Z-
dc.date.issued2022-11-
dc.identifier.issn0923-7534-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/194594-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherOxford University Press-
dc.relation.isPartOfANNALS OF ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleMARIPOSA-2: Randomized phase III study of amivantamab plus lazertinib plus chemotherapy vs chemotherapy alone in EGFRmutant NSCLC after osimertinib failure-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorJ. Wang-
dc.contributor.googleauthorR. Garcia Campelo-
dc.contributor.googleauthorN. Girard-
dc.contributor.googleauthorN. Leighl-
dc.contributor.googleauthorK. Reckamp-
dc.contributor.googleauthorT. Takahashi-
dc.contributor.googleauthorS. Li-
dc.contributor.googleauthorD. Millington-
dc.contributor.googleauthorP. Barala-
dc.contributor.googleauthorJ.M. Bauml-
dc.contributor.googleauthorR.E. Knoblauch-
dc.contributor.googleauthorB.C. Cho-
dc.identifier.doi10.1016/j.annonc.2022.10.500-
dc.relation.journalcodeJ00171-
dc.identifier.eissn1569-8041-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0923753422046919-
dc.citation.volume33-
dc.citation.numberSuppl 9-
dc.citation.startPageS1597-
dc.identifier.bibliographicCitationANNALS OF ONCOLOGY, Vol.33(Suppl 9) : S1597, 2022-11-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.